NCT06978062View on ClinicalTrials.gov

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 20, 2026

Primary Completion Date

September 11, 2028

Study Completion Date

September 28, 2029

Conditions
GastroEsophageal Cancer
Interventions
DRUG

Bemarituzumab

• Bemarituzumab will be given as a IV infusion

DRUG

FLOT

FLOT will be given as a IV infusion

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK